Austria: Mircrobial Technology Joint Development Program in Pharmaceutical Research
The Austrian provider of services for protein expression, VTU Technology, and Boehringer Ingelheim, a global research-driven pharmaceutical company, expand their global technology collaboration.
Grambach and Vienna/Austria – After completion of a first development program, followed by prolonged collaboration, Boehringer Ingelheim is now widening the technological scope. The collaboration includes the advancement of Boehringer Ingelheim’s E. coli expression platform in addition to the competitive optimization of Pichia pastoris platforms for the production of biopharmaceuticals.
“This collaboration gives VTU certain access rights to Boehringer Ingelheim’s proprietary E. coli expression technologies broadening our range of services”, said Dr. Thomas Purkarthofer, Head of Business Development of VTU Technology.
“Widening our cooperation with VTU Technology increases our capabilities and resources for the development of microbial based biopharmaceutical processes. Including E. coli based expression systems to the existing successful cooperation will strengthen our technology leadership and add significant potential for both companies“, said Georg Klima, Executive Director Process Science Austria at Boehringer Ingelheim.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 44026640)